Description: After listening to experts address various topics that affect our work as appointed actuaries, take the time to discuss these issues with yourpeers. The Smaller Insurance Company/Chief Actuary Forum presents a unique format for focusing on issues faced by actuaries in leadership positions or actuaries supporting the Chief Actuary. By discussing critical issues with your peers, you will leave with ideas to incorporate in your business environment. The Forum will feature presentations to introduce three of the discussion topics, followed by an opportunity to break into smaller discussion groups and rotate among topics. By attending the session, you will: Be able to better determine how torespond to some of the challenges you face and establish relationships with other actuaries experiencing similar issues.

Description: The SOA’s Committee on Life Insurance Company Expenses (CLICE) has submitted its recommendation for the 2024 Generally Recognized Expense Table (GRET) for use with individual life insurance sales illustrations.

Description: Update on IFRS 17 including news, how IFRS 17 is impacting companies financials, comparisons to LDTI, and KPIs.

Description: Discuss inforce management techniques that go beyond the traditional methods of adjusting nonguaranteed elements within contractual limits during this webcast. Key methods reviewed include retention, cross-selling/up-selling, wellness, exchange programs and other customer behavior initiatives. Throughout this session, you'll be able to identify methods of inforce management beyond NGE management. You'll also understand the regulatory, legal, operational and financial considerations that will assist with the decision of pursuing this type of management.

Description: The qualification of life insurance under Sections 7702 and 7702A can often be complex and result in inadvertent instance of noncompliance for life insurance companies. This session with explore the complexities of product tax compliance from a due diligence perspective as well as discuss other alternatives companies may have as they administer reductions in benefit under Section 7702A.

Description: This article details different methods for calculating mortality impact associated with new underwriting programs. A common simplified calculation is compared and contrasted with two first principles approaches. The strengths and weaknesses of both approaches are discussed.

Description: This research utilized an interview-based approach that delves into the utilization of alternative data in the Australian life and health insurance markets.

Description: Forward looking insurers are reimagining their businesses with key strategic aims around how they engage with their customers and how they make and implement decisions. Industry experts will present a maturity framework for assessing your progress with specific case studies for how to advance in the areas of Management Information, New Business, and Inforce Management.

Description: There are a number of ways insurers can deploy their capital. Lately the chase for yield, the need for long-tailed risk optimization, and a refocusing on core competencies have driven recent capital trends in the industry. M&A activity has been hot lately, private equity firms have grown their involvement in the industry, and insurers have continued to innovate in their funding of new business strain and investment into customer experience. In this session we will discuss these trends as we study insurer capital optimization through M&A, offshore, and structured reinsurance.

Description: What if a blood test can detect more than 50 types of cancer, including those in early stages? A biotech company, GRAIL, has developed the first-to-market Multi-Cancer Early Detection test and launched it for commercial use in 2021. Join us to learn how Munich Re and GRAIL are partnering to bring its Galleri test to the life insurance industry. You will also explore how we as an industry can help save lives by detecting cancer earlier and share perspectives on some early findings and cost-benefit analysis